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Constant infusion clearance techniques using exogenous
renal markers are considered the gold standard for assessing
the glomerular filtration rate. Here we describe a constant
infusion clearance method in rats allowing the real-time
monitoring of steady-state conditions using an automated
closed-loop approach based on the transcutaneous
measurement of the renal marker FITC-sinistrin. In order to
optimize parameters to reach steady-state conditions as fast
as possible, a Matlab-based simulation tool was established.
Based on this, a real-time feedback-regulated approach for
constant infusion clearance monitoring was developed. This
was validated by determining hourly FITC-sinistrin plasma
concentrations and the glomerular filtration rate in healthy
and unilaterally nephrectomized rats. The transcutaneously
assessed FITC-sinistrin fluorescence signal was found to
reflect the plasma concentration. Our method allows the
precise determination of the onset of steady-state marker
concentration. Moreover, the steady state can be monitored
and controlled in real time for several hours. This procedure
is simple to perform since no urine samples and only one
blood sample are required. Thus, we developed a real-time
feedback-based system for optimal regulation and
monitoring of a constant infusion clearance technique.
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Glomerular filtration rate (GFR) is accepted as the best
measure of overall kidney function. This article focuses on the
constant infusion clearance (CIC) technique. Besides bolus
clearance techniques, CIC is accounted as a gold standard for
GFR assessment. Both methods are based on the disappearance
velocity of exogenous renal markers. Inulin or iothalamate are
frequently used markers in laboratory animals.1
The term ‘gold standard’ implies that the CIC technique
describes a precise procedure with optimized protocols.
However, in literature a vast variety of CIC protocols can be
found. Some typical protocols are given in Table 1.
A prerequisite for correct CIC results is the establishment
of a steady-state marker concentration in the distribution
volume (DV) before plasma and urine samples are taken.
To achieve this steady state as fast as possible, a loading dose
of the marker substance is administered in most protocols
(Table 1). Besides the loading dose, the infused maintenance
dose is strongly influencing the time to equilibrium. One
major reason for the large variation in the published
protocols is the missing knowledge of the maintenance dose
needed to stabilize the concentration in the DV. Thus, also a
large variation in infusion time (25–120min) for establishing
steady-state condition can be noted (Table 1).
To develop an optimized CIC protocol, a simulation tool
was established. On the basis of the simulations, a real-time
feedback-regulated approach for the monitoring of CIC was
developed and validated in rat models. Several studies show
that fluorescent renal markers allow the transcutaneous
measurement of changes in marker concentrations. However,
all these studies use bolus clearances.12–16 In this paper, a CIC
protocol (closed loop protocol) using a fluorescent marker is
described.
The feedback regulation system is based on the fluorescent
renal marker fluorescein isothiocyanate-sinistrin (FITC-
S)14,17–19 and its transcutaneous measurement in the inter-
stitial fluid by a miniaturized device published recently.15 The
new technique allows the exact identification of the steady-
state marker concentration and the monitoring of its
maintenance in real time over the entire study period.
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RESULTS
Infusion clearance simulation
Simulated fluorescence intensity curves were prepared under
the assumption of a constant FITC-S infusion (0.16mg/min
per 100 g body weight (bw)) after varying loading doses in
three models having different kidney functions (Figure 1).
Furthermore, curves were calculated for a fixed loading dose
(5mg/100 g bw FITC-S) followed by different maintenance
infusion doses (Figure 2). These simulations demonstrate
that the optimal setting for a CIC protocol with a short
equilibration time largely relies on the ratio between the
loading and maintenance infusion dose. In addition, this
optimal ratio strongly depends on renal function (Figure 3),
resulting in a variation of the optimal loading dose (mg/100 g
bw)/maintenance infusion dose (mg/min per 100 g bw) ratios
in the simulated animal groups (Sprague–Dawley (SD) rat:
31.5; unilateral nephrectomized rat (UNX): 55; and PKD/
Mhm rat: 57.5). These data indicate that the determination of
a proper loading and maintenance infusion dose needs an
a priori knowledge of the expected magnitude of GFR.
Animal experiments
The CIC feedback regulation system (Figure 4) was tested in
three groups of rats: healthy older SD rats, UNX rats, and
healthy young (y) SD rats (Table 2). Mean arterial pressure
(MAP) and fluorescence intensity of a representative run of
a CIC experiment are depicted in Figure 5. Both parameters
are stable during the entire experiment. Stable experimental
conditions are confirmed by constant GFR and MAP values
in all groups (Table 2).
A considerable variation within the experimental
groups was observed in the peak fluorescence signals after
the bolus injection, with values ranging from 77 to 184, 134
to 251, and 78 to 177 (AU) in the SD, UNX, and ySD groups,
respectively. The fluorescence reference levels were adjusted
individually according to the peak fluorescence. Table 2
Table 1 | Examples of CIC protocols using fructans (inulin, sinistrin) as renal markers in male rats of different strains
demonstrate considerable variability
Maintenance infusion
Study Rat strain Marker
Body weight
or age Loading dose Dose Concentration Flow rate
Proposed equili-
bration time (min) GFR
Feng et al.2 SD Inulin 200–300 g 0 2.5mg/min 100mg/ml 0.025ml/min 60 1.01ml/min per g kw
Nielsen et al.3 SD Inulin 180–220 g Exists Exists Exists 0.025ml/min 120 1.176ml/min per g kw
Dieperink et al.4 SD Sinistrin 140–200 g 17mg/100 g bw 1.085mg/min 31mg/ml 0.035ml/min 120 1.181ml/min per g kw
Nielsen et al.5 SD Sinistrin 140–200 g Exists Exists Exists 0.025ml/min 120 1.079ml/min per g kw
Wilhelm et al.6 SDri Inulin 250–300 g 5mg/100 g bw 0.1mg/min per
100 g bw
10ml/ml 0.01ml/min per
100 g bw
30 0.041ml/min per 100 g bw
Fischer et al.7 Wistar Inulin 350–400 g 1.6mg/100 g
bw
1.98mg/min 36mg/ml 0.055ml/min 105 1.14ml/min per 100 g bw
Haylor et al.8 Lewis Inulin 7w 104mg 0.45mg/min per
100 g bw
9mg/ml 0.05ml/min per
100 g bw
60 0.78ml/min per 100 g bw
Amuchastegui
et al.9
Lewis Inulin 150–250 g Exists 0.8mg/min 40mg/ml 0.02ml/min 60 0.4–0.67ml/min per 100 g bw
Dehmel et al.10 hREN Inulin 181±26 g 0 0.66mg/min per
100 g bw
20mg/ml 0.033ml/min per
100 g bw
25 0.9–1.5ml/min per g kw
Churchill et al.11 John Rapp Inulin 6–8w 20mg/100 g bw 2.09mg/min 38mg/ml 0.055ml/min 60 1.12ml/min per 100 g bw
Abbreviations: bw, body weight; CIC, constant infusion clearance; GFR, glomerular filtration rate; kw, kidney weight; SD, Sprague–Dawley; SDri, Sprague–Dawley after renal
ischemia; w, week.
Studies mentioning a loading dose without further specification are marked as ‘exists’ in the ‘loading dose’ column.
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Figure 1 | Simulated constant infusion clearance runs using fixed infusion dose but varying loading doses. Simulated interstitial
fluorescence intensity curves based on a fluorescein isothiocyanate-sinistrin (FITC-S) infusion dose of 0.16mg/min per 100 g body weight
(bw) without (a) and after a loading dose of 5 (b) or 10mg/100 g bw FITC-S (c) in rats with different glomerular filtration rate (GFR)
conditions (solid lines: healthy Sprague–Dawley, dashed lines: with unilateral nephrectomy, dotted lines: PKD/Mhm rats). Independent of
the GFR level, a short equilibration time of 0.5 h is obtained when the maintenance dose receives the peak fluorescence signal after
loading dose.
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summarizes the results of the experiments including absolute
GFR values assessed by FITC-S plasma concentrations and
maintenance infusion flow rates (IFR), bw-normalized GFR,
MAP, extent of p-controller offset, and equilibration time.
Significant differences between SD and UNX groups were
found in the GFR per 100 g bw (P¼ 0.0005), absolute GFR
(Po0.0001), and MAP (P¼ 0.004) using multifactor analysis
of variance (ANOVA). The multifactor ANOVA between SD
and ySD groups revealed a significant difference in GFR per
100 g bw (Po0.0001), but not in absolute GFR (P¼ 0.8685).
DISCUSSION
The CIC method for GFR assessment relies on establishing
and maintaining steady-state concentrations of a renal mar-
ker in its DV. This requires exact replacement of the filtered
marker by infusion. Using conventional protocols, the onset
of steady state can neither be determined nor monitored in
real time. Equilibration times up to 120min are reported.
Our CIC simulations indicate that steady-state conditions
can be mostly obtained within this time period; however, this
cannot be taken for granted (Figures 1–3). In addition, the
simulations revealed that an a priori knowledge of the
magnitude of the expected GFR is required in order to select
proper CIC parameters, such as loading and maintenance
dose. This is especially true in animals with a reduction in
GFR (Figures 1–3).
The introduced method allows monitoring of changes in
the concentration of the exogenous GFR marker FITC-S
transcutaneously in rats, using a recently invented fluorescence
measuring device.15 The onset of the steady state can exactly be
identified in real time. Furthermore, the maintenance of the
steady state can be monitored and controlled over the entire
time period of the experiment (Table 2 and Figure 5).
As shown in the CIC simulations (Figures 1 and 2), the
shortest time to reach steady-state marker concentrations in
the animals is to maintain the peak concentration after the
loading dose. Therefore, a CIC real-time feedback system was
developed that allows the setting of a bolus response–depen-
dent reference fluorescence level. Once the reference level is set,
the closed-loop regulation determines the optimal mainte-
nance infusion dose automatically. Thus, equilibration time is
optimized in every single animal. This feature is especially
beneficial as the transcutaneously measured fluorescence
intensity peak of a loading bolus can vary considerably, despite
normalization on bw. Besides inter-individual variations in
pharmacokinetics, skin thickness and color, as well as the angle
between skin and excitation light, might explain the variability.
The individual dosing of the renal marker is an improve-
ment in contrast to previous CIC procedures, where the
equilibration time and CIC parameters have to be deter-
mined empirically for each new animal model. By using the
feedback-regulated technique, pilot studies are no longer
needed. Therewith, the technique helps to reduce stress to the
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Figure 2 | Simulated constant infusion clearance runs using
varying infusion doses and a fixed loading dose. Simulated
interstitial fluorescence intensity curves based on a loading dose
of 5mg/100 g body weight (bw) and followed by a maintenance
infusion dose of 0.02 (a), 0.1 (b), 0.2 (c), and 0.4mg/min per
100 g bw (d) in rats with different glomerular filtration rate
conditions (for more details see Figure 1). Equilibration time is
prolonged markedly and varies up to more than 4 h depending
on the chosen dosing parameters.
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Figure 3 |Optimized constant infusion clearance parameters. Simulation results of fluorescein isothiocyanate-sinistrin loading dose,
maintenance infusion dose, and equilibration time (color coded) based on various animal models are depicted (healthy Sprague–Dawley
(a), with unilateral nephrectomy (b), and PKD/Mhm rats (c)). Optimal loading dose/maintenance infusion dose ratio for each animal
model is clearly identified.
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animals (if used in the pilot and the final study) or to
minimize the number of animals required for experiments. In
this study, a steady state was reached in the ySD group in
49±7min, in the older SD group in 73±14min, and in the
UNX group in 81±25min after the FITC-S loading bolus.
The same Kp value of the p-controller (Equation 3) was
used in all three rat models. This explains the significantly
faster equilibration times in the ySD group compared with
the SD and UNX rats. In consequence to the identical Kp
value, the same variation in fluorescence intensity results in
the same change in the FITC-S IFR in all three rat models.
Toal et al.20 showed in Wistar–Kyoto rats that the absolute
extracellular fluid volume (plasma volumeþ interstitial
volume) is higher in 12-week-old rats compared with 6-
week-old rats. Owing to the larger DV but same Kp in the
older rats, the system response time and therewith equilibra-
tion time is longer in older animals. To shorten the equili-
bration time in the older animals, a body weight–dependent
Kp adjustment might be helpful.
21 However, the data demon-
strate that our system is able to achieve steady state in about
50 to 110min in each case.
GFR can only be calculated from the transcutaneous signal
if this is directly proportional to the plasma concentration.
This was confirmed in a previous study.15
In Table 2, the GFR values calculated from the FITC-S
plasma concentrations and Equation 5 (Materials and
Methods section) are given. Multifactor ANOVAs revealed
that the time-related factors (time and time group factor)
have no significant effect on the GFR levels. This indicates
that the method is effective in controlling steady-state
conditions over time. Therefore, GFR can be precisely
calculated from a single blood sample using Equation 5.
A significant difference in GFR between the SD rats and
UNX rats was noted (multifactor ANOVA: GFR per 100 g bw:
P¼ 0.0005; absolute GFR: Po0.0001). In the UNX group, the
absolute and body weight–normalized GFR was reduced by
about 40% compared with the SD control group (Table 2).
This decrease is comparable to published CIC measurements
in healthy rats and rats 16 h, 22 h, and 52 h after UNX.22
However, the body weight–normalized GFR values are lower
in both groups (control: 0.56±0.20ml/min per 100 g bw,
UNX: 0.35±0.20ml/min per 100 g bw) when compared with
the literature (Table 1). In many of these studies, younger
animals with a lower bw were used (Table 1). In 1983,
Provoost et al.23 demonstrated that the overall GFR in adult
Wistar rats is stable over a wide range of bw. As bw increases
with age, there seems to be a linear decline in the relationship
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Figure 4 | Schematic drawing of the regulation loop for
constant infusion clearance. Arrangement and basic
components are shown, including the fluorescence detector,
controller implemented on a host PC for the regulation of the
infusion pump, and the compartments of marker distribution such
as blood, interstitial fluid (IF), and urine.
Table 2 | Summary of constant infusion clearance experiments
Group
Blood
sampling MAP (mmHg)
GFR (ml/min
per 100g bw)
Absolute
GFR (ml/min)
Fluorescence
intensity (% of
reference value)
Plasma FITC-S
concentration
(mg/ml) IFR (ml/min)
Equilibration
time (min)
Body
weight (g)
SD BL 91.0±10.0 0.55±0.18 2.49±0.45 95±2 0.109±0.035 0.0248±0.0062
1 h 95.5±3.0 0.54±0.22 2.44±0.65 95±1 0.105±0.033 0.0241±0.0067
2 h 90.0±3.0 0.58±0.24 2.55±1.00 94±3 0.100±0.026 0.0232±0.0102
Mean 92.2±6.4 0.56±0.20 2.49±0.67 94±2 0.105±0.030 0.0240±0.0075 73±14 467±73
UNX BL 110.4±19.1 0.32±0.14 1.50±0.46 96±3 0.195±0.042 0.0285±0.0083
1 h 105.2±17.6 0.33±0.10 1.58±0.31 95±3 0.181±0.032 0.0286±0.0071
2 h 105.5±20.3 0.34±0.12 1.62±0.43 97±2 0.172±0.030 0.0280±0.0091
Mean 107.0±17.8 0.33±0.11 1.57±0.38 96±2 0.183±0.034 0.0284±0.0077 81±25 493±77
ySD BL 87.2±15.1 1.09±0.24 2.68±0.54 96±2 0.098±0.016 0.0261±0.0040
1 h 96.7±17.1 0.98±0.17 2.40±0.41 97±3 0.096±0.017 0.0233±0.0071
2 h 98.8±10.9 1.00±0.21 2.49±0.59 96±2 0.094±0.022 0.0235±0.0085
Mean 94.2±14.7 1.02±0.20 2.52±0.50 96±2 0.096±0.017 0.0243±0.0065 49±7 251±57
Abbreviations: BL, baseline; FITC-S, fluorescein isothiocyanate-sinistrin; GFR, glomerular filtration rate; IFR, infusion flow rate; MAP, mean arterial pressure; SD, Sprague–Dawley
rats; UNX, unilateral nephrectomy; ySD, young Sprague–Dawley rats.
Values are given as mean±s.d., n=6.
Kidney International (2012) 82, 314–320 317
D Schock-Kusch et al.: Online feedback–controlled renal infusion clearance o r ig ina l a r t i c l e
between normalized GFR and bw. Therefore, our feedback
system was also tested in younger animals. The results of the
ySD group clearly demonstrate that the low normalized GFR
values in our study can be assigned to the higher bw in the SD
and UNX groups (Table 2). The bw-normalized GFR values in
the ySD group are in the expected range.7,22,24 The multifactor
ANOVA between SD and ySD group also revealed a significant
difference in the normalized GFR (Po0.0001), but not in the
absolute GFR (P¼ 0.8685). Hence, the normalization of GFR
to bw in rats should be used with caution (for further details
see supplemental data section online).23
The stable MAP in all groups suggests an adequately
performed anesthesia during the experiments (Table 2). The
significantly higher values in the UNX group compared with
the SD group (multifactor ANOVA, factor group, P¼ 0.004)
might be explained by an excessive salt and water retention
due to the reduced renal capacity.25,26
The difference between reference fluorescence level and
maintained fluorescence level shown in Figure 5 and Table 2
is due to the characteristics of the p-controller. The offset,
which is directly proportional to the correcting variable
(here IFR),21 necessitates the correction of the assessed GFR
values explained in Equation 5. To overcome the necessity of
this correction, a PID controller will be implemented into
future systems.
In conclusion, the novel CIC method allows monitoring
relative changes in marker concentration in vivo in real time,
which permits an individually optimized regulation of the
maintenance dose independent of GFR level. Moreover, the
steady-state conditions can be monitored for several hours
and GFR can be determined using a single blood sample only.
All these facts simplify and accelerate the CIC procedure and
lead to a substantial increase in accuracy.
MATERIALS AND METHODS
Infusion clearance simulation
The distribution and excretion process of the renal marker FITC-
S14,17–19 (FITC-labeled active pharmaceutical ingredient of the
commercial GFR marker Inutest Fresenius Kabi, Linz, Austria) in
a CIC experiment was simulated by using Matlab (Mathworks,
Natick, MA). The time periods to achieve steady state with different
combinations of loading doses and maintenance infusion rates at
different GFR levels were simulated.
The FITC-S distribution and excretion process was modeled as a
two-compartment linear time-invariant system. The input of the
system is the flow rate of the maintenance infusion based on
the output of the fluorescence intensity measured transcutaneously.
The loading process was described as an impulse response due to its
short duration. Therefore, the marker kinetic was expressed as a
second-order impulse response function:
iðtÞ ¼ Aðeat  ebtÞ; ð1Þ
where A is a bolus dose–related constant. The animal model–specific
rate constants a and b were taken from clearance curves of healthy
SD, UNX, and PKD/Mhm rats of previous investigations.15
The transfer function of the second-order linear system was
determined as follows:
IðsÞ ¼ A a bðsþ aÞðsþ bÞ ; ð2Þ
where s is an auxiliary variable introduced with the Laplace
transform.
Each combination of loading and maintenance dose corresponds
to a specific input signal, and the response curve of the system is
acquired using I(s).27–29
Setup of the regulation loop system
The regulation loop system consists of a miniaturized fluorescence
detector equipped with a wireless radio frequency data transfer
module that can be mounted on a shaved part of a rat’s back.15 The
detector sends the data measured to a host computer with software
implemented for data processing. The software controls a syringe
pump (Fusion 100, Chemyx, Stafford, TX), equipped with FITC-S
solution for application via a catheter into the femoral vein of the
animals (Figure 4).
Transcutaneously measured fluorescence data were acquired once
per second by the fluorescence detector (illumination time: 10ms).
The data were analyzed in real time by the software and used for the
regulation of the FITC-S IFR. The IFR was regulated every 10 s by
the controller software.
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Figure 5 | Exemplary run using the real-time feedback
constant infusion clearance system in a Sprague–Dawley
(SD) rat. Mean arterial pressure (MAP, a) and fluorescence
intensity (b) of a representative continuous infusion clearance
experiment run by the real-time feedback system in an
anaesthetized SD rat. Fluorescein isothiocyanate-sinistrin loading
dose of 4mg/100g body weight (bw) was followed by a steady
infusion of 0.015ml/min (10mg/ml). Horizontal line in b marks
the chosen fluorescence reference level. Regulation loop starts
40min (vertical line 0) after bolus. BL (baseline), 1 h, and 2 h
indicate time of blood sampling for plasma concentration
measurement. Stable conditions are demonstrated by the course
of the curves for both parameters during the constant infusion
clearance measurement period of 2.5 h.
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Controller software
The software for the operation of the CIC monitor was based on a
p-controller21 in order to regulate the IFR to reach and maintain a
bolus response–dependent reference fluorescence level. The output
of the controller was limited to positive. Therefore, the IFR was
determined as follows:
IFRðtÞ ¼ KpðIref  iðtÞÞ; ð3Þ
where IFR(t) is the infusion rate determined by the difference
between the measured fluorescence intensity i(t) and the reference
level of the fluorescence intensity Iref. Parameter Kp is the gain of the
feedback controller.21
GFR calculation
Once the fluorescence signal of the renal marker achieves steady
state, the renal marker is assumed to be equally distributed in its DV
under the assumption of a dynamic equilibrium of renal clearance
and infusion rate. Further, GFR can be expressed as follows:
GFR ¼ IFRcinf
cp
; ð4Þ
where cinf represents the FITC-S concentration (mg/ml) of the
infusion solution and cp (mg/ml) is the FITC-S plasma concentra-
tion. Once cp is at steady state, the transcutaneous fluorescence
signal i(t) is also expected to be stable, and therewith GFR is
proportional to the IFR. Therefore, GFR can be determined by a
single blood sample.
Owing to the p-controller-specific regulation offset,21 the GFR
had to be corrected for the reference fluorescence level and achieved
fluorescence level, yielding in the equation:
GFR ¼ IFRcinf
cp
 Iref
iðtsÞ ; ð5Þ
where Iref is the regulation reference fluorescence level and i(ts) is
the fluorescence level at the time of blood sampling.
Animal preparation
All experiments were conducted in accordance with federal and local
laws for the care and use of laboratory animals. Male SPF SD rats
(breeder: Janvier, Le Genest, France) with an age of 12–13 weeks
were obtained for the study to compare the measured GFR in the
older SD (bw: 467±73 g) and UNX rats (bw: 493±77 g). Rats aged
6–7 weeks were used to show the GFR in ySD rats (bw: 251±57 g).
For drug application and blood pressure monitoring, catheters were
inserted into the femoral vein and artery under ketamine (Ketamine
10%, Essex Tierarznei, Munich, Germany; 100mg/kg bw) and
xylazine (Rompun 2%, Bayer, Leverkusen, Germany, 5mg/kg bw)
anesthesia. Catheterization and UNX surgery were performed 1 day
before the CIC experiments as described previously.14
Infusion clearance experiments
During the entire experiment, the animals were anesthetized (intra-
peritoneally, constant infusion, 20mg/ml ketamine: 0.8–1.8ml/h
(Ketamine 10%, Essex Tierarznei). The arterial catheter was connec-
ted to a blood pressure monitor (PAMII preamplifier model, A&R
Elektronik-Service & Vertrieb, Germany).
For the loading, FITC-S (40mg/ml) in Deltajonin (DeltaSelect
GmbH, Rimbach, Germany) was used at a dose of 4mg/100 g bw in
SD and 8mg/100 g bw in UNX rats. To avoid overturning and
oscillation of the system during the regulation process, a constant
infusion of 0.015ml/min (10mg FITC-S/ml in Deltajonin) was
started immediately after the bolus injection.21 As soon as the peak
fluorescence signal was reached, the reference level was set and the
feedback regulation started (about 30–40min after the loading bolus).
Once the standard deviation of the fluorescence intensity was
observed to be o1.2 (AU) in 5min (definition of steady state by
the authors), a first blood sample was drawn (0.2ml via femoral
artery) for fluorometric measurement of FITC-S plasma concentra-
tion14 to calculate the GFR according to Equation 5. Steady state was
maintained by the regulated infusion flow and monitored for another
2.5 h, with blood sampling every hour (three samples in total).
Statistical methods
A 10-min-wide running median filter30 was used to smoothen the
fluorescence intensity and IFR. All regression and statistical analyses
were performed using the SAS statistical software package and its
business unit JMP (SAS Institute, Cary, NC). Multifactor ANOVAs
were performed between the SD vs. UNX group and SD vs. ySD
group to evaluate the effects of possible confounding factors: time
(1 h, 2 h), group (SD vs. UNX and SD vs. ySD), and time group as
interactional factor.
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